11 active not recruiting, 8 completed, 2 recruiting, 2 withdrawn. 17 Phase 2, 11 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 17 | Active not recruiting 9, Completed 3, Recruiting 2, Withdrawn 2, Not yet recruiting 1 |
| Phase 1 | 11 | Completed 6, Active not recruiting 5 |
| Phase 3 | 1 | Active not recruiting 1 |
Follow Oleclumab: new trials by email Literature Review of Oleclumab trials Research Report on Oleclumab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| The Selective Personalized Radio-Immunotherapy for Locally Advanced Non-Small Cell Lung Cancer Trial 2 Durvalumab, Monalizumab, Oleclumab - Non-small Cell Lung Cancer | Phase 2 | Not yet recruiting | Montefiore Medical Center | 52 | 2026-09-01 | 2026-06-09 |
| A Study to Investigate the Effects of Durvalumab With Oleclumab Following Chemoradiation in Participants With Locally Advanced Unresectable Non-Small Cell Lung Cancer (LADOGA) Oleclumab, Durvalumab - Non-Small Cell Lung Cancer | Phase 2 | Active not recruiting | AstraZeneca | 30 | 2024-09-24 | 2026-05-15 |
| Durvalumab and Oleclumab in Resectable PDAC Durvalumab, Oleclumab - Pancreatic Ductal Adenocarcinoma | Phase 2 | Recruiting | University Health Network, Toronto | 22 | 2023-11-29 | 2026-06-23 |
| Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer Durvalumab, Oleclumab, Monalizumab - Non-small Cell Lung Cancer | Phase 2 | Recruiting | AstraZeneca | 630 | 2022-04-14 | 2026-10-21 |
| A Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer Durvalumab, Oleclumab, Monalizumab - Non-Small Cell Lung Cancer | Phase 3 | Active not recruiting | AstraZeneca | 1051 | 2022-02-07 | 2026-06-18 |
| Gemcitabine, Nab-paclitaxel, Durvalumab, and Oleclumab Before Surgery for the Treatment of in Resectable/Borderline Resectable Primary Pancreatic Cancer Durvalumab, Gemcitabine, Nab-paclitaxel - Borderline Resectable Pancreatic Adenocarcinoma, Resectable Pancreatic Adenocarcinoma | Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 13 | 2021-09-28 | 2026-10-07 |
| A Multi-Cancer, Multi-State, Platform Study of Durvalumab (MEDI4736) and Oleclumab (MEDI9447) in Pancreatic Adenocarcinoma, Non-Small Cell Lung Cancer and Squamous Cell Carcinoma of the Head and Neck to Correlate Clinical, Molecular and Immunologic Parameters With DNA Methylation Durvalumab, Oleclumab - Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer | Phase 2 | Withdrawn | University Health Network, Toronto | 2021-01-01 | 2020-11-17 | |
| A Phase 2 Study of Durvalumab (MEDI4736) and Oleclumab (MEDI9447) in Multi-Cancer Populations With Correlation to Clinical, Molecular and Immunologic Parameters With DNA MethylaTION Durvalumab, Oleclumab - Non Small Cell Lung Cancer, Renal Cell Carcinoma | Phase 2 | Withdrawn | University Health Network, Toronto | 2021-01-01 | 2020-11-17 | |
| Oleclumab and Durvalumab for the Treatment of Recurrent, Refractory, or Metastatic Sarcoma Durvalumab, Oleclumab - Metastatic Angiosarcoma, Metastatic Dedifferentiated Liposarcoma | Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 75 | 2020-11-26 | 2026-06-22 |
| IPH5201 as Monotherapy or in Combination With Durvalumab +/- Oleclumab in Subjects With Advanced Solid Tumors. IPH5201, durvalumab, oleclumab - Advanced Solid Tumors | Phase 1 | Completed | MedImmune LLC | 57 | 2020-03-03 | 2022-08-15 |
| Neo-adjuvant Chemotherapy Combined With Stereotactic Body Radiotherapy to the Primary Tumour +/- Durvalumab, +/- Oleclumab in Luminal B Breast Cancer: Durvalumab, Stereotactic Body Radiotherapy, Oleclumab - Luminal B | Phase 2 | Active not recruiting | Jules Bordet Institute | 147 | 2019-11-06 | 2026-10-07 |
| Testing the Safety of Adding Either Monalizumab (IPH2201) or Oleclumab (MEDI9447) to Durvalumab (MEDI4736) Plus Standard Radiation Therapy for Locally Advanced Non-small Cell Lung Cancer (NSCLC), ARCHON-1 Trial Accelerated Hypofractionated Radiation Therapy, Biospecimen Collection, Computed Tomography - Locally Advanced Lung Non-Small Cell Carcinoma, Locally Recurrent Lung Non-Small Cell Carcinoma | Phase 1 | Completed | National Cancer Institute (NCI) | 26 | 2019-10-28 | 2025-09-23 |
| COLUMBIA-1: Novel Oncology Therapies in Combination With Chemotherapy and Bevacizumab as First- Line Therapy in MSS-CRC Durvalumab, Oleclumab, FOLFOX - Metastatic Microsatellite-stable Colorectal Cancer | Phase 1 / Phase 2 | Active not recruiting | MedImmune LLC | 61 | 2019-09-13 | 2026-08-11 |
| An Open-label, Phase II Study of AZD4635 in Patients With Prostate Cancer AZD4635, Oleclumab, Durvalumab - Prostate Cancer, Metastatic Castration-Resistant Prostate Cancer (mCRPC) | Phase 2 | Completed | AstraZeneca | 59 | 2019-08-29 | 2024-04-16 |
| Neoadjuvant Durvalumab Alone or in Combination With Novel Agents in Resectable Non-Small Cell Lung Cancer Durvalumab, Oleclumab, Monalizumab - Resectable, Early-stage | Phase 2 | Completed | MedImmune LLC | 84 | 2019-03-08 | 2022-02-24 |
| A Feasibility Study of Durvalumab +/- Oleclumab as Neoadjuvant Therapy for Muscle-invasive Bladder Cancer (BLASST-2) Durvalumab, Oleclumab - Muscle Invasive Bladder Cancer | Phase 1 | Completed | Dana-Farber Cancer Institute | 12 | 2019-02-20 | 2022-09-13 |
| Paclitaxel + Carboplatin + Durvalumab With or Without Oleclumab for Previously Untreated Locally Recurrent Inoperable or Metastatic TNBC Paclitaxel, Carboplatin, MEDI4736 - Triple Negative Breast Cancer | Phase 1 / Phase 2 | Active not recruiting | Jules Bordet Institute | 129 | 2018-12-28 | 2026-10-07 |
| A Study of Novel Anti-cancer Agents in Patients With Previously Untreated NSCLC Durvalumab, Danvatirsen, Oleclumab - Metastatic Non-Small Cell Lung Cancer (NSCLC) | Phase 1 | Active not recruiting | AstraZeneca | 175 | 2018-12-27 | 2026-05-12 |
| A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast Cancer Durvalumab, Capivasertib, Oleclumab - Triple Negative Breast Neoplasms | Phase 1 / Phase 2 | Active not recruiting | AstraZeneca | 243 | 2018-12-21 | 2026-08-04 |
| MEDI9447(Oleclumab) Pancreatic Chemotherapy Combination Study. Oleclumab, Durvalumab, Gemcitabine - Carcinoma, Metastatic Pancreatic Adenocarcinoma | Phase 1 / Phase 2 | Completed | MedImmune LLC | 213 | 2018-06-21 | 2023-10-03 |
Showing 20 of 24. Sign in to see all of them.
Carcinoma, Non-Small-Cell Lung (12) · Breast Neoplasms (3) · Lung Neoplasms (3) · Neoplasms (2) · Pancreatic Neoplasms (2) · Prostatic Neoplasms (2) · Triple Negative Breast Neoplasms (2) · Bronchial Neoplasms (1) · Carcinoma (1) · Carcinoma, Bronchogenic (1) · Carcinoma, Renal Cell (1) · Colonic Neoplasms (1) · Colorectal Neoplasms (1) · Hemangiosarcoma (1) · Liposarcoma (1)
AstraZeneca (8) · MedImmune LLC (6) · University Health Network, Toronto (3) · Jules Bordet Institute (2) · M.D. Anderson Cancer Center (2) · Dana-Farber Cancer Institute (1) · Montefiore Medical Center (1) · National Cancer Institute (NCI) (1)
United States (18) · Canada (9) · France (8) · Spain (8) · South Korea (7) · Taiwan (5) · Australia (4) · Belgium (4) · Italy (3) · Poland (3) · Portugal (3) · Austria (2) · Germany (2) · Russia (2) · Switzerland (2)
Albiruni Razak, MD (1) · Alex De Caluwe, MD (1) · Brandon G Smaglo (1) · Chih-Hsin Yang, MD (1) · Fabrice Barlesi, MD (1) · Johanna Bendell, MD (1) · John Heymach, M.D, Ph.D (1) · Laurence Buisseret (1) · Lillian Siu, MD (1) · Malcolm Moore, MD (1) · Neeta Somaiah (1) · Nitin R Ohri, MD (1) · Peter Schmid, MD, PhD (1) · Sandip Patel, MD (1)
PMID 27622077, PMID 34362344, PMID 36641093, PMID 37016126, PMID 37707791, PMID 38056900, PMID 38351187, PMID 38430405, PMID 39023287, PMID 39048638, PMID 40450142, PMID 41380462, PMID 42259988, PMID 42350643
2018 (3), 2023 (3), 2017 (1), 2019 (1), P30CA016672 (1), U10CA180868 (1)